Nuvectis Pharma annual current ratio
2021
2022
2023
2024
2025
Nuvectis Pharma Current Ratio Growth & History (NVCT)
Nuvectis Pharma's current ratio was 2.38 for fiscal 2025.
View full Nuvectis Pharma company overviewNuvectis Pharma annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 2.38 | 0.29 | +13.99% |
| 2024 | 2024-12-31 | 2.09 | −0.65 | −23.84% |
| 2023 | 2023-12-31 | 2.75 | −0.55 | −16.72% |
| 2022 | 2022-12-31 | 3.30 | 0.89 | +36.80% |
| 2021 | 2021-12-31 | 2.41 | — | — |
Nuvectis Pharma quarterly current ratio
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 1.68 | −0.98 | −36.84% |
| Q1 2026 | 2026-03-31 | 2.27 | −1.01 | −30.71% |
| Q4 2025 | 2025-12-31 | 2.38 | 0.29 | +13.99% |
| Q3 2025 | 2025-09-30 | 3.07 | 0.33 | +12.18% |
| Q2 2025 | 2025-06-30 | 2.66 | −0.51 | −15.97% |
| Q1 2025 | 2025-03-31 | 3.28 | −0.18 | −5.32% |
| Q4 2024 | 2024-12-31 | 2.09 | −0.65 | −23.84% |
| Q3 2024 | 2024-09-30 | 2.74 | −1.25 | −31.37% |
| Q2 2024 | 2024-06-30 | 3.17 | −2.24 | −41.40% |
| Q1 2024 | 2024-03-31 | 3.46 | −0.66 | −15.94% |
| Q4 2023 | 2023-12-31 | 2.75 | −0.55 | −16.72% |
| Q3 2023 | 2023-09-30 | 3.99 | −1.54 | −27.88% |
| Q2 2023 | 2023-06-30 | 5.41 | 0.21 | +4.06% |
| Q1 2023 | 2023-03-31 | 4.12 | −1.64 | −28.47% |
| Q4 2022 | 2022-12-31 | 3.30 | 0.89 | +36.80% |
| Q3 2022 | 2022-09-30 | 5.54 | — | — |
| Q2 2022 | 2022-06-30 | 5.20 | — | — |
| Q1 2022 | 2022-03-31 | 5.76 | — | — |
| Q4 2021 | 2021-12-31 | 2.41 | — | — |
Nuvectis Pharma current ratio trends
Between the periods ended 2021-12-31 and 2025-12-31, Nuvectis Pharma's current ratio decreased from 2.41 to 2.38, a change of −0.03. The latest reported quarter, Q2 2026, shows 1.68.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nuvectis Pharma source filings ↗